Brief: Anaptys Announces Phase 2B Trial Of ANB032, A BTLA Agonist, Did Not Meet Endpoints

AnaptysBio

11/12/2024 13:44

Dec 11 (Reuters) - AnaptysBio  ANAB.O :
    * ANAPTYS ANNOUNCES PHASE 2B TRIAL OF ANB032, A BTLA
AGONIST, DID
NOT MEET PRIMARY OR SECONDARY ENDPOINTS IN ATOPIC DERMATITIS
    * ANAPTYSBIO INC: ANTICIPATE TOP-LINE PHASE 2B DATA IN
RHEUMATOID
ARTHRITIS IN FEBRUARY 2025
    * ANAPTYSBIO INC - ANB032 AD TRIAL AND ALL FURTHER
INVESTMENT 
WILL BE DISCONTINUED
    * ANAPTYSBIO INC - ANB032 WELL TOLERATED WITH NO SAFETY
SIGNALS
OBSERVED
    * ANAPTYSBIO INC - YEAR-END 2024 CASH ABOUT $415 MILLION

Source text:  ID:nGNXbd61Yl 
Further company coverage:  ANAB.O 

 ((Reuters.Briefs@thomsonreuters.com;))